Aytu BioPharma Q2 fiscal 2026 net loss $10.6M; EXXUA launch generates $0.2M initial revenue

AYTU BIOPHARMA, INC

2026-Q2 EPS reported -$0.89 revenue$29,053,000

Net revenue $15.2M, down 6% YoY; net loss $10.6M vs net income $0.8M, includes $8.2M derivative warrant liability loss.
Adjusted EBITDA -$0.8M vs +$1.3M, driven by EXXUA launch investments; cash $30.0M.
ADHD portfolio revenue $13.2M (down from $13.8M); pediatric $1.7M (down from $2.4M) due to marketing deemphasis.
EXXUA launched Dec 2025; initial stocking revenue $0.2M; 40+ person sales force deployed targeting $22B MDD market.
Cash and cash equivalents $30.0M, largely unchanged from $31.0M at June 30, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.